COVID 2026 Surge: Symptoms to Watch and the New Xocova Prevention Pill
Last updated: 2026-08-27 · Published: 2026-08-27
With infections climbing in nearly every state, public-health officials are pointing to a twice-a-year COVID pattern and a newly approved oral pill meant to stop illness after exposure. Here is what people need to know during the late-summer 2026 wave.
What is happening: COVID-19 activity is increasing across the United States, with infections growing or likely growing in 47 states, according to Centers for Disease Control and Prevention (CDC) data cited by regional news outlets. The rise arrives as federal research identifies a recurring pattern of two distinct COVID peaks each year, and as the medication Xocova becomes available as a post-exposure prevention option.
Key facts at a glance
| What | Late-summer COVID-19 surge across the U.S. |
| Scope | Infections growing or likely growing in 47 states (CDC data) |
| Pattern | COVID tends to peak twice a year — late summer and winter |
| Symptoms | Stomach-related complaints (nausea, vomiting, diarrhea) reported more often this surge |
| Prevention | Xocova — FDA-approved oral pill for people 12 and older to take after exposure |
| Efficacy | Cut the risk of symptomatic COVID by about 67% in the company’s trial, per news reports |
| Also advised | Handwashing, avoiding close contact, staying home when unwell, fall flu shots from September |
Why COVID now peaks twice a year
Unlike influenza, which mostly surges in winter, COVID-19 routinely shows a second spike in late summer, according to CDC research highlighted in local health coverage. The twice-a-year cycle appears tied to how quickly the virus mutates, letting new variants spread outside the usual respiratory-virus season while national flu activity stays low.
Seasonal factors add to the late-summer uptick. Summer heat pushes more people indoors, and students returning to school create extra chances for the virus to move through a community.
“We have seen Covid spikes in summer in the past before. And unfortunately, it seems like this year there is a spike in Covid over the summer as well,” Dr. Bradley Jacoby, Chief of Service for Pediatrics at Kaiser Permanente Riverside, told News Channel 3 in California. He added that immunity wanes over time and the virus keeps mutating, so people who had COVID months ago can face renewed risk.
What the 2026 summer surge looks like
Doctors say the symptoms turning up during this wave are shifting. Beyond the familiar respiratory signs, patients are reporting more stomach-related issues, including nausea, vomiting and diarrhea. Anyone feeling unwell is advised to test, avoid close contact with others, and stay home rather than risk spreading the virus.
Public-health guidance for lowering risk remains straightforward: wash hands regularly, steer clear of close contact with people who are sick, and avoid crowded indoor settings when case numbers are high.
Xocova: a new option after exposure
The FDA earlier this year approved Xocova (ensitrelvir), made by Japan’s Shionogi, as the first oral antiviral for people 12 and older to take after being exposed to someone with COVID. The five-day pill is intended to block viral replication before symptoms develop. In the manufacturer’s study, the pill reduced the risk of developing symptomatic COVID by about 67%; common side effects include headache, diarrhea and cough.
It gives people who know they had close contact with an infected person a way to act quickly instead of waiting to see whether they get sick. “If they’re around somebody in their family or just in a place where they know there was a contact with a Covid positive person, they can request this medication to help prevent them from coming down with Covid,” Dr. Jacoby said.
Xocova should be taken under a doctor’s guidance. Health officials also stress it does not replace vaccines, and people should still ask a clinician whether the pill is right for their situation.
Watch: What the videos show
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
The manufacturer’s announcement video covers how the drug works as a five-day, at-home pill for people exposed to the virus, and the role the FDA approval plays for U.S. prevention options.
FDA Approves First Pill to Prevent COVID-19 After Exposure — WTHR report
This broadcast segment explains the practical details for patients: the five-day regimen, approval for ages 12 and up, the roughly 67% reduction in symptomatic illness, and the common side effects to expect. Transcript points below come from this report.
Confirmed versus not confirmed
| Confirmed | Not confirmed |
| Infections growing or likely growing in 47 states, per CDC data | Any claim that this surge is more dangerous than earlier waves |
| COVID shows a recurring late-summer and winter peak pattern | A single new symptom that applies to every patient |
| Xocova is FDA-approved for ages 12+ after COVID exposure | That Xocova prevents all infections or is a cure |
| Trial showed roughly 67% reduction in symptomatic COVID | That Xocova replaces vaccines or other prevention measures |
An appearance of symptoms or a single news clip does not establish a medical diagnosis for any individual. Anyone concerned about COVID should consult a health-care provider for testing, treatment, and advice tailored to their situation.
Frequently asked questions
Why is COVID spiking in late summer 2026?
CDC research identifies a recurring pattern of two COVID peaks a year. The summer rise is driven partly by frequent virus mutation and by conditions that bring people indoors and back to school, giving the virus more chances to spread.
What are the symptoms to watch for during this surge?
Familiar respiratory symptoms appear, but doctors say more patients are reporting stomach-related issues such as nausea, vomiting and diarrhea during this wave. Anyone unwell should test and stay home.
What is Xocova and who can take it?
Xocova (ensitrelvir) is a five-day oral antiviral from Japan’s Shionogi, approved for people 12 and older to help prevent COVID after exposure. It should be used under a doctor’s guidance.
How well does Xocova work?
In the manufacturer’s clinical trial, the pill reduced the risk of developing symptomatic COVID by about 67%. It is not a cure and does not replace vaccination.
Does Xocova have side effects?
News reports list common side effects including headache, diarrhea and cough. Patients should review risks and benefits with their provider.
Besides Xocova, how can people reduce risk now?
Wash hands regularly, avoid close contact with sick people, stay home if unwell, and get the fall flu shot between September and the end of October as officials recommend.
Related stories
- Germany Reports Record 15,800 Heat Deaths This Summer
- What Mitch McConnell’s Resurfaced Senate Video Shows — and What It Doesn’t
- Delta Captain Hospitalized Mid-Flight: LA to Boston Flight Diverts to Detroit
Sources: KESQ News Channel 3 (via Storyful), CDC, Reuters, WebMD, Fierce Pharma, Shionogi / BusinessWire, WTHR
